NY-SNOWPLUS
4.6.2021 01:02:05 CEST | Business Wire | Press release
Snowplus , a leading global vape company, and its global business have flourished despite challenges posed by the COVID pandemic that has impacted business around the world. Their strategy of localization implemented in late 2019 has proven to be the key to their continual growth in the face of the pandemic. Since the pandemic started they have still seen a growth increase of around 350% in their global business.
Business impacts of the pandemic have been far reaching, including but not limited to logistics, manufacturing, and local economies being shut down. For the vape industry, it has been no different. However, localized strategies have enabled responsive and agile decision making, and have also minimized any negative impact from the current unforeseen global crisis.
Local Partners
In multiple new markets Snowplus has expanded to, they’ve been able to partner with leading companies that know their local markets well. To win the confidence of top level partners, a combination of quality products, reliable support, and long term investment have proven to be the key.
“Our focus on producing consistently high quality, rigorously tested products have helped us win major partnerships in markets we expand to,” explained Derek Li, Snowplus Cofounder and Head of Overseas Markets. “It’s always a satisfying moment when potential partners test our products, have a ‘wow’ moment, and come back to us ready to work something out.”
Local Strategies
In Canada, Snowplus realized quickly that finding a respected local e-liquid partner would bring down costs associated with e-liquid production and international shipping. But even more importantly, the Canadian palate was quite different from the flavors that make Snowplus pods a hit in Asia. Instead of hoping to have the market warm up to different taste profiles, tailoring flavors that fit local vapers has netted immediate market growth.
In fact, Canada is not the only market where Snowplus implements this two-pronged strategy of establishing local partners and executing local strategies. As a result, not only is Snowplus one of the fastest growing vape brands in the world according to device shipments since they started in 2019, they’ve achieved record growth during the pandemic.
“From our 28-point testing, the most thorough in the industry, to our high-tech laboratories in Shenzhen, our dogged dedication to product quality has opened doors for us in new markets and won over market leading partners wherever we go,” said Li. “In turn, it's been relatively easy for us to work with our local partners and trust their strategies, which has really carried us through this past year of difficulty. In the end, to still achieve record growth has been something we’re extremely proud of and grateful for. We’re not done. As the world slowly emerges from the pandemic, we’re open to any partners that are ready to work with us. Just reach out.”
ABOUT SNOWPLUS
Founded in April 2019, Snowplus is dedicated to replacing combustible tobacco through consistent quality and a commitment to innovating better vaping experiences. Snowplus products have passed a number of third-party safety certifications and are made with components that meet the highest medical safety standards. To date, Snowplus has received over $150 million in financing which is among the largest funding for any startup in the e-cigarette industry.
To learn more about Snowplus, please go to snowplustech.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom